Medical/Pharmaceuticals
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...
2026-04-23 16:22
3584
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026-04-23 15:02
1113
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative lo...
2026-04-23 10:19
1057
Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...
2026-04-23 06:30
3871
GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists
PISCATAWAY, N.J., April 23, 2026 /PRNewswire/ -- GenScript Biotech Corporation
2026-04-23 04:03
1818
Chulalongkorn University doctors successfully performed surgery for obstructive sleep apnea using the new HGNS technique the fourth successful surgery of this kind in Asia
BANGKOK, April 22, 2026 /PRNewswire/ -- The Excellence Center for Sleep
Disorders,King Chulalongkorn Memorial Hospital, Thai Red Cross Society
2026-04-22 14:54
3159
AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore
SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a c...
2026-04-22 14:13
3481
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with...
2026-04-22 14:10
966
Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...
2026-04-22 11:09
2539
NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes
An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier. ...
2026-04-22 11:00
3668
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 Investment of a...
2026-04-22 10:00
3070
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...
2026-04-22 08:59
3409
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...
2026-04-22 08:00
3569
Dawn Medical Technologies Acquires Controlling Interest in Pinnacle Health in Vietnam
* Strategic entry into high-growth Vietnam market * Combines Dawn's product sourcing capabilities with Pinnacle Health's established local presence and market expertise * Advances Dawn's mission to expand access to high-quality, affordable medical technologies across Southeast Asia SINGAPORE...
2026-04-22 08:00
3854
Keung To Appointed Official Brand Ambassador for Herbalgy and Touch Cool
KEEP ME UP. HOLD TIGHT. KEEP GOING.
Limited-Edition Collectible Keychains Drop Now
Your Bag, Your Keys, Your Everyday
Download high-resolution images: https://bit.ly/4tw4GyF
2026-04-21 21:30
3906
Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone
GOTHENBURG, Sweden, April 21, 2026 /PRNewswire/ -- "We succeeded in surpassing last year's record-breaking first quarter with organic growth in both net sales and order intake," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 0.8% while th...
2026-04-21 20:36
2508
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety t...
2026-04-21 20:00
2653
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...
2026-04-21 10:00
3678
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...
2026-04-20 18:45
2959
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per sha...
2026-04-20 10:36
4381
Week's Top Stories
Most Reposted
Visa Destinations Launches in Asia Pacific as Regional Travel Remains Resilient
[Picked up by 327 media titles]
2026-05-05 10:01Amadeus outlines intention to acquire Idemia Public Security (IPS) for €1.2 billion, to create seamless end-to-end travel journeys of the future
[Picked up by 300 media titles]
2026-04-29 14:31AVPN AI Opportunity Fund Expands to Build AI-Ready Generations Across Asia by Empowering Educators and Youth Across Asia-Pacific
[Picked up by 295 media titles]
2026-05-05 09:00Colebrook Bosson Saunders Expands Flo X Multi Compatibility for Curved Ultrawide Monitors
[Picked up by 288 media titles]
2026-05-05 11:00
REVIVING HERITAGE: REBIRTH OF A LEGACY
[Picked up by 282 media titles]
2026-04-30 16:24
Most Read
TCL TECH 2025 Net Profit Surges 188.8%, Led by Strong Display Performance
2026-05-01 15:29
8449
Delixy Holdings Limited Reports Fiscal Year 2025 Financial Results
2026-05-01 04:30
8151
